15 Best S&P 500 Dividend Stocks to Buy Now

4. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 88

Bristol-Myers Squibb Company (NYSE:BMY) is an American pharmaceutical industry company. In the fourth quarter of 2024, the company reported revenue of $12.34 billion, reflecting a 7.5% increase compared to the same period the previous year. The company’s Growth Portfolio performed particularly well, with revenue climbing 21% to $6.4 billion. This growth was driven by strong demand for key treatments, including Reblozyl, Breyanzi, and Camzyos, which saw annual sales increases of 71%, 125%, and 101%, respectively.

Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing new molecular entities while also pursuing strategic acquisitions to bolster its research and development capabilities. This approach enhances its competitive positioning, fosters innovation, and solidifies its presence in the pharmaceutical industry. In the past 12 months, the stock has surged by over 16%.

Bristol-Myers Squibb Company (NYSE:BMY) ended the year with more than $10.3 billion in cash and cash equivalents. The company is considered as one of the best dividend stocks, having consistently paid dividends for 93 years and increasing its payouts for 16 consecutive years. Currently, it pays a quarterly dividend of $0.60 per share and has a dividend yield of 4.18%, as of February 27.